A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
Conditions
Alzheimer's Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Montreal Neurological Institute Clinical Research Unit, Montreal, Quebec, Canada
Brain Research Center Amsterdam, Amsterdam, North Holland, Netherlands
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hospital Universitario Reina Sofia, Córdoba, Spain
Sahlgrenska Universitetssjukhuset, Mlndal, Sweden
Karolinska Universitetssjukhuset, Solna, Sweden
Institute of Psychiatry, Psychology and Neuroscience;Department of Old Age Psychiatry, London, Greater London, United Kingdom
Southampton General Hospital, Southampton, Hampshire, United Kingdom
Queen Elizabeth Hospital, Glasgow, Strathclyde, United Kingdom
National Hospital For Neurology and Neurosurgery, London, United Kingdom
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche